Health Economics · 2004 · 710 citations · 3 references
PharmacyEconomicsPharmacoeconomicsHealth EconomicsHealth Technology AssessmentHealthcare EconomicsCost-effectiveness ThresholdsEconomic EvaluationHealthcare Cost AnalysisPerspective In Economic EvaluationPharmacoeconomic EvaluationThreshold AnalysisBinary AnalysisCost-effectivenessCost-effectiveness Acceptability ThresholdsDecision Threshold AnalysisHealth Economic ReviewMinimum Cost-effectiveness ThresholdsQaly GainsQaly Thresholds
NICE’s decisions raise questions about how cost‑effectiveness evidence informs value‑for‑money judgments and how non‑cost factors are incorporated. This study investigates NICE’s cost‑effectiveness threshold(s) and the trade‑offs between cost‑effectiveness and other influencing factors in its decisions. Using binary choice analysis, the authors model NICE’s accept/reject decisions with explanatory variables such as cost per QALY, uncertainty, net cost, disease burden, alternative availability, and NICE‑specified factors. The analysis confirms a cost‑effectiveness threshold, with rejection probability rising as cost per QALY rises, and shows that cost effectiveness combined with uncertainty and disease burden better predicts decisions than cost alone, suggesting a threshold higher than NICE’s stated £20,000–£30,000 per QALY range. © 2004 John Wiley & Sons, Ltd.
Abstract The decisions made by the National Institute for Clinical Excellence (NICE) give rise to two questions: how is cost‐effectiveness evidence used to make judgements about the ‘value for money’ of health technologies? And how are factors other than cost‐effectiveness taken into account? The aim of this paper is to explore NICE's cost‐effectiveness threshold(s) and the tradeoffs between cost effectiveness and other factors apparent in its decisions. Binary choice analysis is used to reveal the preferences of NICE and to consider the consistency of its decisions. For each decision to accept or reject a technology, explanatory variables include: the cost per life year or per QALY gained; uncertainty regarding cost effectiveness; the net cost to the NHS; the burden of disease; the availability (or not) of alternative treatments; and specific factors indicated by NICE. Results support the broad notion of a threshold, where the probability of rejection increases as the cost per QALY increases. Cost effectiveness, together with uncertainty and the burden of disease, explain NICE decisions better than cost effectiveness alone. The results suggest a threshold somewhat higher than NICEs stated ‘range of acceptable cost effectiveness’ of £20 000–£30 000 per QALY – although the exact meaning of a ‘range’ in this context remains unclear. Copyright © 2004 John Wiley & Sons, Ltd.
3